Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study

• Published in: Diabetes, Obesity and Metabolism Obesity and Metabolism, 2021-05, Vol.23 (5), p.1162-1172
• Main Authors: Roussel, Ronan, Darmon, Patrice, Pichelin, Matthieu, Goronflot, Thomas, Abouleka, Yawa, Ait Bachir, Leila, Allix, Ingrid, Ancelle, Deborah, Barraud, Sara, Bordier, Lyse, Carlier, Aurélie, Chevalier, Nicolas, Coffin‐Boutreux, Christine, Cosson, Emmanuel, Dorange, Anne, Dupuy, Olivier, Fontaine, Pierre, Fremy, Bénédicte, Galtier, Florence, Germain, Natacha, Guedj, Anne‐Marie, Larger, Etienne, Laugier‐Robiolle, Stéphanie, Laviolle, Bruno, Ludwig, Lisa, Monier, Arnaud, Montanier, Nathanaëlle, Moulin, Philippe, Moura, Isabelle, Prevost, Gaëtan, Reznik, Yves, Sabbah, Nadia, Saulnier, Pierre‐Jean, Serusclat, Pierre, Vatier, Camille, Wargny, Matthieu, Hadjadj, Samy, Gourdy, Pierre, Cariou, Bertrand
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - drug therapy; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Dipeptidyl-peptidase IV; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; DPP‐4 inhibitor; Endocrinology and metabolism; Female; Human health and pathology; Humans; Infectious diseases; Intubation; Life Sciences; Male; Mechanical ventilation; Medical prognosis; Middle Aged; Observational studies; observational study; Original; Pandemics; Patients; Peptidase; Prognosis; Propensity Score; Regression analysis; type 2 diabetes
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14324

Aim To investigate the association between routine use of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and the severity of coronavirus disease 2019 (COVID‐19) infection in patient with type 2 diabetes in a large multicentric study. Materials and Methods This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID‐19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP‐4 inhibitors users vs. non‐users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW). Results Five hundred and ninety‐six participants were under DPP‐4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non‐users of DPP‐4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW‐adjusted models showed no significant association between the use of DPP‐4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77–1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78–1.17]). Similar neutral findings were found between use of DPP‐4 inhibitors and the risk of tracheal intubation and death. Conclusions These data support the safety of DPP‐4 inhibitors for diabetes management during the COVID‐19 pandemic and they should not be discontinued.